In recent years, GLP-1 receptor agonists, widely known for their effectiveness in managing Type 2 diabetes and promoting weight loss, have gained attention for their potential benefits in other areas […]
December 9, 2024 8:30 AM – 5:00 PM Hilton Miami Dadeland 9100 N. Kendall Drive, Miami, FL 33176 This full-day conference on Alzheimer’s features discussions on Pathophysiology, Biomarkers, Diagnosis, Anti-Amyloid
First Choice Neurology, the largest neurology group in the United States, is set to make medical history this week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum are among the
First Choice Neurology Administers New Alzheimer’s Drug Kisunla Read More »
Are you familiar with Kisunla, the newly FDA-approved medication for Alzheimer’s disease? The Food and Drug Administration approved Lilly’s Kisunla (donanemab) earlier this week for mild or early cases of
KISUNLA: The NEW Alzheimer’s FDA Approved Medication Read More »
According to a study led by researchers at UCLA, the Alzheimer’s drug Leqembi would raise future costs for Medicare by $2 billion to $5 billion a year. Leqembi, sold for
Study finds Alzheimer’s drug Leqembi would cost Medicare up to $5 billion a year Read More »
A late-stage clinical trial was conducted by Biogen and Eisai and the new Alzheimer’s drug they are developing for Alzheimer’s disease slowed the rate of cognitive decline. New Alzheimer’s Drug
Research Study Shows New Alzheimer’s Drug Slows Cognitive Decline Read More »
Jeff Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, is scheduled to treat the first patient in Florida with Biogen’s Aducanumab (Aduhelm), a monthly
First Florida Patient to Receive Biogen Aducanumab Infusion Read More »
In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause
Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the
Do you suffer from post-COVID-19 syndrome, also referred to as COVID-19 Long-Haulers? Symptoms may include fatigue, shortness of breath, headaches, dizziness, trouble sleeping, and brain fog, or difficulty thinking clearly.
